Wang Yang, Chen Chen, Hu Gui-Lin, Chu Chao, Zhang Xiao-Yu, Du Ming-Fei, Zou Ting, Zhou Qing, Liao Yue-Yuan, Ma Qiong, Wang Ke-Ke, Sun Yue, Wang Dan, Yan Yu, Li Yan, Jia Hao, Niu Ze-Jiaxin, Zhang Xi, Wang Lan, Man Zi-Yue, Gao Wei-Hua, Li Chun-Hua, Zhang Jie, Gao Ke, Li Hui-Xian, Chang John, Desir Gary V, Lu Wan-Hong, Mu Jian-Jun
Department of Cardiovascular Medicine, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Key Laboratory of Molecular Cardiology of Shaanxi Province, Xi'an, China.
Front Cardiovasc Med. 2022 Feb 24;9:800427. doi: 10.3389/fcvm.2022.800427. eCollection 2022.
Renalase, a novel secretory flavoprotein with amine oxidase activity, is secreted into the blood by the kidneys and is hypothesized to participate in blood pressure (BP) regulation. We investigated the associations of renalase with BP and the risk of hypertension by examining renalase single nucleopeptide polymorphism (SNPs), serum renalase levels, and renal expression of renalase in humans.
① Subjects ( = 514) from the original Baoji Salt-Sensitive Study cohort were genotyped to investigate the association of renalase SNPs with longitudinal BP changes and the risk of hypertension during 14 years of follow-up. ② Two thousand three hundred and ninety two participants from the Hanzhong Adolescent Hypertension Study cohort were used to examine the association of serum renalase levels with hypertension. Renalase expression in renal biopsy specimens from 193 patients were measured by immunohistochemistry. ③ Renalase expression was compared in hypertensive vs. normotensive patients.
① SNP rs7922058 was associated with 14-year change in systolic BP, and rs10887800, rs796945, rs1935582, rs2296545, and rs2576178 were significantly associated with 14-year change in diastolic BP while rs1935582 and rs2576178 were associated with mean arterial pressure change over 14 years. In addition, SNPs rs796945, rs1935582, and rs2576178 were significantly associated with hypertension incidence. Gene-based analysis found that renalase gene was significantly associated with hypertension incidence over 14-year follow-up after adjustment for multiple measurements. ② Hypertensive subjects had higher serum renalase levels than normotensive subjects (27.2 ± 0.4 vs. 25.1 ± 0.2 μg/mL). Serum renalase levels and BPs showed a linear correlation. In addition, serum renalase was significantly associated with the risk of hypertension [ = 1.018 (1.006-1.030)]. ③ The expression of renalase in human renal biopsy specimens significantly decreased in hypertensive patients compared to non-hypertensive patients (0.030 ± 0.001 vs. 0.038 ± 0.004).
These findings indicate that renalase may play an important role in BP progression and development of hypertension.
肾酶是一种具有胺氧化酶活性的新型分泌性黄素蛋白,由肾脏分泌入血,据推测其参与血压(BP)调节。我们通过检测肾酶单核苷酸多态性(SNP)、血清肾酶水平以及肾酶在人体肾脏中的表达,研究肾酶与血压及高血压风险之间的关联。
① 对来自原宝鸡盐敏感性研究队列的受试者(n = 514)进行基因分型,以研究肾酶SNP与14年随访期间血压纵向变化及高血压风险的关联。② 来自汉中青少年高血压研究队列的2392名参与者用于研究血清肾酶水平与高血压的关联。采用免疫组织化学法检测193例患者肾活检标本中肾酶的表达。③ 比较高血压患者与血压正常患者的肾酶表达。
① SNP rs7922058与收缩压14年变化相关,rs10887800、rs796945、rs1935582、rs2296545和rs2576178与舒张压14年变化显著相关,而rs1935582和rs2576178与14年平均动脉压变化相关。此外,SNP rs796945、rs1935582和rs2576178与高血压发病率显著相关。基于基因的分析发现,在对多次测量进行校正后,肾酶基因与14年随访期间的高血压发病率显著相关。② 高血压受试者的血清肾酶水平高于血压正常受试者(27.2±0.4 vs. 25.1±0.2μg/mL)。血清肾酶水平与血压呈线性相关。此外,血清肾酶与高血压风险显著相关[比值比 = 高1.018(1.006 - 1.030)]。③ 与非高血压患者相比,高血压患者肾活检标本中肾酶的表达显著降低(0.030±0.001 vs. 0.038±0.004)。
这些发现表明肾酶可能在血压进展和高血压发生中起重要作用。